Anticoagulant Effects of Low Molecular Weight Heparin

Mechanism of Action

The American College of Chest Physicians recommends that low molecular weight heparin (LMWH) exerts its anticoagulant effect mainly by activating antithrombin (AT), potentiating the inhibition of Factor Xa and, to a lesser extent, the inhibition of thrombin (Factor IIa), resulting in an anti-Xa:anti-IIa ratio of 2:1 to 4:1 1
The LMWH binds to AT through a specific pentasaccharide sequence, producing a conformational change in the arginine reactive center of AT, converting AT from a slow to a fast inhibitor of serine proteases 1, 5
For thrombin inhibition, a minimum of 18 saccharide units (including the pentasaccharide sequence) are required for the heparin chain to bind simultaneously to AT and thrombin 6, 1

The European Society of Cardiology notes that LMWHs have a lower capacity for binding to plasma proteins, resulting in a more predictable dose-response relationship 2, 1
LMWHs have a lower affinity for macrophages and endothelial cells, increasing their plasma half-life compared to unfractionated heparin (UFH) 2, 1
They have a lower affinity for platelets and platelet factor 4 (PF4), which explains the lower incidence of heparin-induced thrombocytopenia 2, 1
LMWHs are eliminated primarily through the renal route, and their biological half-life is prolonged in patients with renal insufficiency 2, 6

The American Heart Association suggests that LMWH can be administered once daily by subcutaneous injection without the need for coagulation monitoring due to its more predictable pharmacokinetics 1, 5
The anti-Xa:anti-IIa ratio of commercial LMWHs varies between 2:1 and 4:1, depending on their molecular size distribution 1
Currently, there is no evidence that differences in the anti-Xa:anti-IIa ratio between different LMWHs influence clinical outcomes such as recurrence of thrombosis or hemorrhagic complications 1